Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. Its lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.
Reneo Pharmaceuticals, Inc. Frequently Asked Questions
What is the ticker symbol for Reneo Pharmaceuticals, Inc.? What does RPHM stand for in stocks?
RPHM is the stock ticker symbol of Reneo Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Reneo Pharmaceuticals, Inc. (RPHM)?
As of Mon Dec 02 2024, market cap of Reneo Pharmaceuticals, Inc. is 48.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of RPHM stock?
You can check RPHM's fair value in chart for subscribers.
Is Reneo Pharmaceuticals, Inc. a good stock to buy?
The fair value guage provides a quick view whether RPHM is over valued or under valued. Whether Reneo Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Reneo Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for RPHM.